Compare IBCP & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBCP | OMER |
|---|---|---|
| Founded | 1864 | 1994 |
| Country | United States | United States |
| Employees | 270 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 703.3M | 772.8M |
| IPO Year | 2010 | 2008 |
| Metric | IBCP | OMER |
|---|---|---|
| Price | $35.46 | $8.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.00 | $32.50 |
| AVG Volume (30 Days) | 100.5K | ★ 1.7M |
| Earning Date | 04-23-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | 3.48 | ★ 98.15 |
| EPS | ★ 0.81 | 0.62 |
| Revenue | ★ $32,075,000.00 | $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.98 | $233.22 |
| P/E Ratio | $43.60 | ★ $16.42 |
| Revenue Growth | ★ 0.30 | N/A |
| 52 Week Low | $29.63 | $2.95 |
| 52 Week High | $37.39 | $17.65 |
| Indicator | IBCP | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 24.11 |
| Support Level | $32.22 | $8.27 |
| Resistance Level | $35.54 | $12.06 |
| Average True Range (ATR) | 0.69 | 0.77 |
| MACD | 0.17 | -0.12 |
| Stochastic Oscillator | 84.29 | 40.39 |
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.